This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with mantle cell lymphoma.

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

• Identify the biologic factors related to prognosis in mantle cell lymphoma (MCL)
• Review efficacy data on the use of traditional, anthracycline-based therapies for patients with MCL
• Summarize data from clinical trials that are investigating novel therapies for MCL
• Describe the efficacy of emerging treatments for MCL

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity will disclose the existence of any financial interest and/or relationship(s) theymight havewith themanufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Faculty Disclosures
André Goy, MD, MS is on the speaker's bureau and is a consultant for Allos, Biogen Idec, Celgene, Genentech, and Millennium.

*Steven Bernstein, MD is a consultant for Enzon, Genentech, Millennium, and Mundipharma.

Jeanne Held-Warmkessel, MSN, RN, AOCN®, ACNS-BC is on the advisory board for Merck, and is on the speaker's bureau for Cephalon and Novartis.

Meredith Moorman, PharmD, BCOP has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.